These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193 [TBL] [Abstract][Full Text] [Related]
65. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. Miyamoto E; Chen-Yoshikawa TF; Ueshima C; Yoshizawa A; Hamaji M; Yamamoto T; Kawada K; Haga H; Sakai Y; Date H J Surg Oncol; 2018 Jun; 117(7):1405-1412. PubMed ID: 29663398 [TBL] [Abstract][Full Text] [Related]
66. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Aoki T; Hino M; Koh K; Kyushiki M; Kishimoto H; Arakawa Y; Hanada R; Kawashima H; Kurihara J; Shimojo N; Motohashi S Pediatr Blood Cancer; 2016 Aug; 63(8):1461-4. PubMed ID: 27135656 [TBL] [Abstract][Full Text] [Related]
68. Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Wang L; Ren F; Wang Q; Baldridge LA; Monn MF; Fisher KW; Sheng W; Zhou X; Du X; Cheng L Mol Diagn Ther; 2016 Apr; 20(2):175-81. PubMed ID: 26891728 [TBL] [Abstract][Full Text] [Related]
69. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533 [TBL] [Abstract][Full Text] [Related]
70. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells). Yoshida N; Kinugasa T; Miyoshi H; Sato K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y; Ohshima K Ann Surg Oncol; 2016 Mar; 23(3):919-27. PubMed ID: 26564244 [TBL] [Abstract][Full Text] [Related]
71. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470 [TBL] [Abstract][Full Text] [Related]
72. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827 [TBL] [Abstract][Full Text] [Related]
73. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures]. Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846 [TBL] [Abstract][Full Text] [Related]
74. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049 [TBL] [Abstract][Full Text] [Related]
75. Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. Chang J; Zhu GA; Cheung C; Li S; Kim J; Chang AL JAMA Dermatol; 2017 Apr; 153(4):285-290. PubMed ID: 28259105 [TBL] [Abstract][Full Text] [Related]